Chemours (NYSE:CC) released its earnings results on Thursday. The specialty chemicals company reported $0.18 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.09 by $0.09, MarketWatch Earnings reports. Chemours had a negative net margin of 2.28% and a positive return on equity of 46.11%. The firm had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.08 billion.

NYSE CC traded up $0.53 on Friday, hitting $18.53. The stock had a trading volume of 2,800,605 shares, compared to its average volume of 1,468,352. Chemours has a 52-week low of $7.02 and a 52-week high of $20.23. The company has a debt-to-equity ratio of 6.42, a quick ratio of 1.10 and a current ratio of 1.93. The company has a market capitalization of $3.04 billion, a price-to-earnings ratio of -25.74 and a beta of 2.44. The firm has a 50-day moving average of $15.99 and a 200-day moving average of $13.88.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Monday, August 17th will be paid a $0.25 dividend. This represents a $1.00 annualized dividend and a yield of 5.40%. The ex-dividend date is Friday, August 14th. Chemours’s dividend payout ratio is presently 39.84%.

A number of research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Chemours from a “strong sell” rating to a “hold” rating and set a $17.00 target price for the company in a research report on Tuesday, July 7th. Citigroup reduced their target price on shares of Chemours from $10.00 to $8.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. ValuEngine cut shares of Chemours from a “hold” rating to a “sell” rating in a research note on Wednesday, July 15th. SunTrust Banks upped their price target on shares of Chemours from $10.00 to $12.00 and gave the company a “hold” rating in a research note on Thursday, May 7th. Finally, Cfra dropped their price target on shares of Chemours from $21.00 to $11.00 and set a “hold” rating on the stock in a research note on Friday, April 3rd. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and two have assigned a buy rating to the company. Chemours has an average rating of “Hold” and a consensus target price of $14.30.

In other news, COO Mark Newman bought 2,500 shares of the stock in a transaction on Thursday, May 7th. The shares were acquired at an average cost of $11.62 per share, for a total transaction of $29,050.00. Following the purchase, the chief operating officer now directly owns 132,344 shares of the company’s stock, valued at approximately $1,537,837.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 2.72% of the company’s stock.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging.

Featured Article: What does cost of debt say about a company’s financial health?

Earnings History for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.